J9298 HCPCS Level II code: Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg
J9298 is the HCPCS code for “Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J9298Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg
Short description: Inj nivol relatlimab 3mg/1mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J9298 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Chemotherapy
- Added
- Oct 1, 2022
Where J9298 sits
- 1J codesDrugs administered other than orally
- 2Active code J9298Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J9298 mean?
J9298 is the HCPCS code for “Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J9298?
CMS lists J9298’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J9298
All J codesJ9292Injection, pemetrexed dipotassium, 10 mgJ9293Injection, mitoxantrone hydrochloride, per 5 mgJ9294Injection, pemetrexed (hospira), not therapeutically equivalent to j9305, 10 mgJ9295Injection, necitumumab, 1 mgJ9296Injection, pemetrexed (accord), not therapeutically equivalent to j9305, 10 mgJ9297Injection, pemetrexed (sandoz), not therapeutically equivalent to j9305, 10 mgJ9299Injection, nivolumab, 1 mgJ9300Injection, gemtuzumab ozogamicin, 5 mgJ9301Injection, obinutuzumab, 10 mgJ9302Injection, ofatumumab, 10 mgJ9303Injection, panitumumab, 10 mgJ9304Injection, pemetrexed (pemfexy), 10 mg